Re: Comments on the AGM

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Have a great Sunday, especially those of you like me that are celebrating Orthodox Easter ... As well as those of you who are also like me and mourning another Maple Leafs Game 7 exit ... Ugggh!

Sincerely,

George et al

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7673 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Comments on the AGM

in response to

Re: Comments on the AGM

sidebar

posted on Nov 11, 2019 02:05AM

sidebar, Fenix, paladin - In theory it would be nice to only license apabetalone for one medical issue, in practice though it is close to impossible. If you have read all the posters that BDAZ has posted in the last few days you will notice that all of these 3 diseases are closely tied together. DRs may not be absolutely certain that their patient has CVD without dementia or declining kidney function. So who's to stop them from scripting a patient for one thing and really having it for another. It is a challenge. For these reasons it is most likely that one company will end up with the patent/license for all indications. That's not 100%, just most likely.

All three of you are reasonably new posters to the RVX Hub. In the past we have discussed this situation a few times. This argument is what makes the possible selling price for ABL so hard for many to grasp. When you add it all up it is almost impossible to come up with annual sales that wouldn't leave Humara in the dust. It's going to be interesting to see how this all ends up.

At this point in time to me, the meeting with the FDA on Wednesday could be the single biggest day in the companies history. To bad they won't be able to tell us anything about it for a month or so.